Literature DB >> 31115011

COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.

G-B Jiang1, H-Y Fang, D-Y Tao, X-P Chen, F-L Cao.   

Abstract

OBJECTIVE: To elucidate the effect of cyclooxygenase 2 (COX-2) on cisplatin resistance of NSCLC and its molecular mechanisms, with special attention to its pro-EMT (epithelial-mesenchymal transition) properties.
MATERIALS AND METHODS: COX-2 levels were compared in two NSCLC cell lines, A549 and H460, by qPCR (quantitative Polymerase Chain Reaction) and Western blot. Cytotoxicity of cisplatin was also determined in the two cell lines using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. The expression of EMT-related proteins and activation of AKT (protein kinase B) signaling were detected in H460 cells with ectopic COX-2 expression.
RESULTS: Cisplatin-induced apoptosis was assessed in COX-2 overexpressing H460 cells by FACS. NS398, a COX-2 inhibitor, was also applied to determine EMT status and effect on cisplatin sensitivity in H460 cells. COX-2 levels were positively correlated with cisplatin resistance in both NSCLC cell lines tested. In response to COX-2 overexpression, EMT-related proteins, such as E-cadherin, were inhibited, while vimentin and N-cadherin were upregulated. The AKT signaling pathway was also activated in H460 cells. Ectopic expression of COX-2 potentiated cisplatin resistance of H460 cells, which was accompanied by decreased levels of apoptosis. Notably, NS398 effectively increased the cytotoxicity of cisplatin in A549 cells by inhibiting EMT and the AKT pathway.
CONCLUSIONS: COX-2 might promote cisplatin resistance in NSCLC by promoting EMT through the AKT signaling pathway activation.

Entities:  

Year:  2019        PMID: 31115011     DOI: 10.26355/eurrev_201905_17811

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma.

Authors:  Junbin Wang; Jin Gao; Qinnan Chen; Weiyan Zou; Fen Yang; Chenchen Wei; Zhaoxia Wang
Journal:  Onco Targets Ther       Date:  2020-09-22       Impact factor: 4.147

2.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

Review 3.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

4.  The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer.

Authors:  Xiao-Mian Lin; Wu Luo; Heng Wang; Rong-Zhen Li; Yi-Shan Huang; Lian-Kuai Chen; Xiao-Ping Wu
Journal:  Front Pharmacol       Date:  2019-08-08       Impact factor: 5.810

Review 5.  Role of ACTN4 in Tumorigenesis, Metastasis, and EMT.

Authors:  Dmitri Tentler; Ekaterina Lomert; Ksenia Novitskaya; Nikolai A Barlev
Journal:  Cells       Date:  2019-11-13       Impact factor: 6.600

Review 6.  MicroRNA-375: potential cancer suppressor and therapeutic drug.

Authors:  Jiahui Wei; Yiran Lu; Ruiqing Wang; Xiangzhu Xu; Qing Liu; Song He; Huihao Pan; Xinmiao Liu; Bao Yuan; Yu Ding; Jiabao Zhang
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

Review 7.  Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment.

Authors:  Julia López de Andrés; Carmen Griñán-Lisón; Gema Jiménez; Juan Antonio Marchal
Journal:  J Hematol Oncol       Date:  2020-10-15       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.